Background: Video-assisted thoracic surgery (VATS) lobectomy has been performed with increasing frequency over the last decade. However, there is still controversy as to its indications, safety, and feasibility. Especially regarding lung cancer surgery, it is not certain whether it can reduce local recurrences and improve overall survival. Materials and Methods: We retrospectively reviewed 1,067 cases of VATS lobectomy performed between 2003 and 2009, in-cluding the indications, postoperative morbidity, mortality, recurrence, and survival rate. Results: One thousand and sixty seven patients underwent VATS lobectomy for the following indications: non-small cell lung cancer (NSCLC) (n=832), carcinoid tumors (n=12), metastatic lung cancer (n=48), and benign or other diseases (n=175). There were 63 cases (5.9%) of conversion to open thoracotomy during VATS lobectomy. One hundred thirty one (15.7%) of the 832 NSCLC patients experienced pathologic upstaging postoperatively. The hospital mortality rate was 0.84% (9 patients), and all of them died of acute respiratory distress syndrome. One hundred forty-nine patients (14.0%) experienced postoperative complications. The median follow-up was 22.9 months for patients with NSCLC. During follow-up, 120 patients had a recurrence and 55 patients died. For patients with pathologic stage I, the overall survival rate and disease-free survival rate at 3 years was 92.2±1.5% and 86.2±1.9%, respectively. For patients with pathologic stage II disease, the overall survival rate and disease-free survival rate at 3 years was 79.2±6.5% and 61.9±6.6%, respectively. Conclusion: Our results suggest that VATS lobectomy is a technically feasible and safe operation, which can be applied to various lung diseases. In patients with early-stage lung cancer, excellent survival can be also achieved.
INTRODUCTION
Throughout the last decade, the number of video-assisted thoracic surgeries (VATS) has increased rapidly [1] [2] [3] . In patients with early stage lung cancer, lobectomy done by using a thoracoscope has been universalized. Technical stability has already been proven and the indication for thoracoscopy is diversifying [4] [5] [6] [7] [8] [9] [10] . However, some researchers have questioned the safety and feasibility of thoracoscopy performed in patients with lung cancer [11] [12] [13] [14] . There is some debate regarding recurrence and survival rates after thoracoscopic lobectomy in patients with early stage non-small cell lung cancer − 170 − [8, 13, [15] [16] [17] [18] [19] . According to Rueth's [20] retrospective results in a study about thoracoscopic lobectomies have done since 1994, post-surgical morbidity and inflammation were lower in patients who had gone through thoracoscopic lobectomy than in patients who had gone through thoracotomic lobectomy. In addition, there was no difference in the 5-year survival rate when comparing the results of thoracoscopic lobectomy with the results of thoracotomic lobectomy. The authors of the present study retrospectively analyzed 1,067 cases of thoracoscopic lobectomy and their indications, conversion rate to thoracotomy during surgery, postsurgical complications, hospital mortality rate, and postsurgical recurrence and survival rate in order to suggest ways to widen the surgical application of the thoracoscopic lobectomy in the future.
MATERIALS AND METHODS
This research received approval from the clinic's institutional review board. 1,067 patients who had gone through Subjects who underwent surgery had lesions that could be excised anatomically and showed reduced pulmonary ventilation on preoperative pulmonary function tests. The subjects' pulmonary diseases were inflammatory diseases such as pulmonary tuberculosis, empyema, congenital pulmonary disease, primary lung cancer, metastatic lung cancer, and carcinoid tumor. In cases with benign pulmonary disease, lobectomy was performed if the majority of the pulmonary lobe was damaged, or segmentectomy or wedge resection could not be executed due to the proximity of the lesion to the central bronchus or vascular structures. However, thoracotomic lobectomy was performed in cases of CT scan evidence of pleural calcification, severe calcification around pulmonary vessels, or thorax deformation. In cases of non-small cell lung cancer, thoracoscopic lobectomy was executed if the preoperative cancer stage was stage I with no endobronchial lesion, if the tumor was located peripherally, or if the diameter of the tumor was less than 6 cm. In cases with a single metastasis to the brain, gamma knife surgery was performed before lobectomy (5 cases). Pulmonary function testing, CT scanning, and PET CT scanning were done preoperatively. If non-small cell lung cancer was diagnosed pathologically before surgery, mediastinal lymph node biopsies were performed in areas 2R, 4R, 4L, and 7 under mediastinoscopy even if there was no evidence of mediastinal lymph node metastasis. If the patient was incapable of going through neoadjuvant chemoradiotherapy due to underlying disease or old age, lobectomy was executed without mediastinoscopy, even if mediastinal lymph node metastasis was suspected. Patients with no diagnosis of preoperative pathological non-small cell lung cancer underwent thoracoscopic wedge resection, the frozen section was then analyzed, and lobectomy was done if it was diagnosed as cancer. The excised pulmonary lobe was removed from the pleural cavity in a plastic pouch to prevent implantation of cancer cells into the thoracic wall [19] . The authors of this research performed thoracoscopy as follows. After general anesthesia, a 10-mm access port for a thoracoscope was made in the seventh or eighth intercostal space of the mid-axillary line to observe the pleural cavity.
Then, a 5 or 10 mm port was made in the seventh intercostal Sixty-three cases (5.9%) converted to thoracotomy during thoracoscopic surgery. Common causes for these conversions were hemorrhage from pulmonary artery branches and difficulties in detaching calcified or fibrous lymph nodes ( Table   2 ).
Nine patients (0.84%) died in the clinic after surgery. All of these patients underwent lobectomy because of non-small cell lung cancer and the cause of death was the same for all cases, acute respiratory distress syndrome. Five patients among them had diffuse interstitial pulmonary disease.
Complications occurred 162 times in 149 patients (14.0%).
The most common complication was continuous air leakage (62 cases) ( Table 3 ). The most common pathological stage of non-small cell lung cancer was stage I with 649 cases (77.6%) ( Table 4 ). The average follow-up observation period of non-small cell lung cancer patients was 22.9 months. The number of patients with relapse during the follow-up observation period was 120, and 55 of them died. Among patients with relapse, 40 patients had local relapse, 58 patients had remote relapse, and 22 patients had both local and remote relapses ( showed increased pathological stage after surgery. The 1-year and 3-year overall survival rates of these patients were 95.7±
1.9% and 82.5±5.0%, respectively. The 1-year and 3-year disease-free survival rates were 85.2±3.4% and 45.9±6.8%, respectively (Fig. 2) . The most common cause of the patho- disease-free survival rates were 81.0±6.1% and 21.4±9.7%, respectively (Fig. 3) .
DISCUSSION
The application of VATS has been expanding from diseases such as benign pleural disease, lung disease, and mediastinal disease [3] to lung cancer and esophageal cancer [22] .
The range of pulmonary resections has also been expanding, currently including pulmonary wedge resection, segmentectomy, lobectomy, bilobectomy, and even pneumectomy [1] .
McKenna et al. [23] reported on the largest number of thoracoscopic lobectomy cases in a single institute. Their thoracoscopic indications were primary lung cancer, lymphoma, metastatic lung cancer, or benign pulmonary disease, which were similar to the author's indications.
A low number of postoperative complications and a low hospital mortality rate have been reported in various articles.
Hospital mortality rate after thoracotomic lobectomy has been found to be similar to that of thoracoscopic lobectomy, whereas postoperative complications were less common in thoracoscopic lobectomy [4, 20, 24] . These results are similar to the results of our study in complication occurrence rate (14.0%, 162 cases) and hospital mortality rate (0.84%).
Among postoperative complications, continuous air leakage was the most common. In order to minimize leakage, a stapler was used for isolation rather than electrocautery or blunt dissection when severe adhesion was present in the interlobar fissure. Then, denuded visceral pleura was covered with absorbable felt or applied with glue to reduce air leakage. There are numerous risk factors affecting hospital mortality. In this study, 5 out of the 9 patients who died in the clinic had diffuse interstitial lung disease. This implies that patients with diffuse interstitial lung disease must cautiously decide whether to undergo a lobectomy, which may compromise lung function after surgery. Since FEV1 levels are often normal based on pulmonary function testing, diffusing capacity (DLco) must be measured and operation should be avoided when DLco levels are low [25] . In addition, VATS is less painful than thoracotomy [26] and has a shorter hospitalization period.
There have been numerous reports regarding the fact that thoracoscopic lobectomy is not oncologically different from thoracotomic lobectomy. Rueth and Andrade [20] showed that there were no oncological differences between thoracoscopic and thoracotomic lobectomy by analyzing research articles about thoracoscopic lobectomy from 1994 to present [8, 17, 18] . Yan et al. [27] showed that the 5-year disease-free survival rate of thoracoscopic lobectomy was significantly higher than that of thoracotomic lobectomy (p=0.03).
Sugi et al. [17] and Watanabe et al. [28] showed that there was no difference in the number of collected lymph nodes, survival rate, and recurrence when comparing thoracoscopic mediastinal lymph node dissection and thoracotomic mediastinal lymph node dissection. Common causes for conversion from thoracoscopic surgery to thoracotomic surgery were
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− 175 − hemorrhage in pulmonary artery branches and difficulty in detaching a calcified or fiberized lymph node. To reduce the conversion rate, preoperative CT should be analyzed thoroughly to check for the calcification or fibrosis of lymph nodes along with thickening.
On the other hand, there are different views about the feasibility of the thoracoscopic lobectomy for lung cancer.
Opponents of insist that thoracoscopic lobectomy results in lower survival rate and higher relapse rate. Thoracoscopic lobectomy may result in more manipulation of the lung, causing cancer cells to disseminate through the pulmonary vein [13] . In addition, excisions with a stapler may leave cancer cells at the resection margin, mediastinal lymph node dissection may be insufficient, and cancer cells may be disseminated while removing the specimen out of the body [19] .
In the author's institute, the pulmonary vein was detached be- However, it is too early to affirm that the postoperative relapse rate of stage I non-small cell lung cancer is low or that stages greater than II have greater postoperative relapse rates.
In order to draw a more accurate conclusion on the relapse and survival rates of patients treated with thoracoscopic lobectomy for early non-small cell lung cancer, long-term follow-up observation is needed. In the previous articles, an analysis of the 5-year overall survival rate after thoracoscopic lobectomy for early stage non-small cell lung cancer was conducted, whereas most of the previous studies have not reported specifics about 5-year disease-free survival rates [15, 18, 20, 23] . Yamamoto et al. [29] recently reported the pa- The consistency of the research results from our clinic was maintained by using the same medical team to perform operations with identical indications and criteria (lymph node biopsy and mediastinal lymph node dissection under mediastinoscopy). Also, with a relatively abundant amount of data (1,067 cases), results such as low morbidity, low hospital mortality, and low conversion rate are acceptable.
In the future, the number of patients with early stage nonsmall cell lung cancer with an indication of thoracoscopic lobectomy will increase. As diagnostic techniques advance, the number of patients with early stage lung cancer is increasing, adenocarcinoma is becoming more common than squamous cell carcinoma. Adenocarcinoma is usually located peripherally, which facilitates a thoracoscopic approach. In addition, the number of female patients with the disease is increasing, in which the aesthetic benefits of thoracoscopic surgery are more preferable. As more thoracoscopic lobectomy experiences are documented in the future, thoracoscopic lobectomy could be applied to the patients in stage II lung cancer or patients with endobronchial cancer needing a sleeve lobectomy.
But more prospective studies are necessary to recognize it as a feasible method of treatment.
Lastly, there are several limitations in this research. First, data was analyzed retrospectively and there were no compar- 
CONCLUSION
Based on our 6 years of experience, thoracoscopic lobectomy is a safe and useful method for treating various pulmonary diseases including early non-small cell lung cancer, without a high complication occurrence rate or hospital mortality rate. In addition, an excellent survival rate was observed in patients with early non-small cell lung cancer.
However, depending on the stage of the disease, continued collection of data may be necessary to observe long-term results.
